November 21, 2019

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoons’ BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

Overall Deal Potential Valued up to $2.4B